Paxman Q3 2026 net profit rises to SEK 7.81 million year over year; Q3 2026 net sales climb 18% to SEK 102.91 million year over year

PUBT · 1d ago
Paxman Q3 2026 net profit rises to SEK 7.81 million year over year; Q3 2026 net sales climb 18% to SEK 102.91 million year over year
  • Paxman’s third-quarter 2026 net profit rose year over year to SEK 7.81 million.
  • Net sales climbed 18% year over year to SEK 102.91 million.
  • Operating cash outflow narrowed year over year to SEK 887,000, with higher trade receivables and inventories weighing on cash flow.
  • The Paxman Neuropathy System launched commercially in early November, marking the first major product expansion beyond scalp cooling.
  • The FDA advanced the neuropathy system’s De Novo application into substantive review in November.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Paxman AB published the original content used to generate this news brief on November 20, 2026, and is solely responsible for the information contained therein.